Genetic signatures shared in embryonic liver development and liver cancer define prognostically relevant subgroups in HCC

Molecular Cancer

Volumn 11, Issue , 2012, Pages

  Becker, Diana ^a   Sfakianakis, Ioannis ^a   Krupp, Markus ^a   Staib, Frank ^a   Gerhold Ay, Aslihan ^b   Victor, Anja ^b   Binder, Harald ^b   Blettner, Maria ^b   Maass, Thorsten ^a   Thorgeirsson, Snorri ^c   Galle, Peter R ^a   Teufel, Andreas ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CELL CYCLE; COMPARATIVE STUDY; EMBRYO DEVELOPMENT; FISHER EXACT TEST; GENE CONTROL; GENE EXPRESSION; HUMAN; LIVER CANCER; LIVER CELL CARCINOMA; LIVER DEVELOPMENT; MICROARRAY ANALYSIS; NONHUMAN; SIGNAL TRANSDUCTION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER; LIVER NEOPLASMS; MICE; PROGNOSIS; SIGNAL TRANSDUCTION;

EID: 84864911464     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-11-55     Document Type: Article

References (43)

1. Caldwell S, Park SH. The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. J Gastroenterol 2009, 44(Suppl 19):96-101.
2. Bosch FX, Ribes J, Borràs J. Epidemiology of primary liver cancer. Semin Liver Dis 1999, 19:271-285.
3. Llovet J, et al. Sorafenib improves survival in advanced Hepatocellular Carcinoma (HCC): Results of a Phase III randomized placebo-controlled trial (SHARP trial). Journal of Clinical Oncology ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement) 2007: LBA1 2007,
4. Tan X, Yuan Y, Zeng G, Apte U, Thompson MD, et al. Beta-catenin deletion in hepatoblasts disrupts hepatic morphogenesis and survival during mouse development. Hepatology 2008, 47:1667-1679.
5. Suksaweang S, Lin CM, Jiang TX, Hughes MW, Widelitz RB, et al. Morphogenesis of chicken liver: identification of localized growth zones and the role of beta-catenin/Wnt in size regulation. Dev Biol 2004, 266:109-122.
6. Hussain SZ, Sneddon T, Tan X, et al. Wnt impacts growth and differentiation in ex vivo liver development. Exp Cell Res 2004, 292:157-169.
7. Monga SP, Monga HK, Tan X, Micsenyi A, Michalopoulos GK, et al. Beta-catenin antisense studies in embryonic liver cultures: role in proliferation, apoptosis, and lineage specification. Gastroenterology 2003, 124:202-216.
8. Matsumoto K, Miki R, Nakayama M, Tatsumi N, Yokouchi Y. Wnt9a secreted from the walls of hepatic sinusoids is essential for morphogenesis, proliferation, and glycogen accumulation of chick hepatic epithelium. Dev Biol 2008, 319:234-247.
9. Giles RH, van Es JH, Clevers H. Caught-up in a Wnt storm: Wnt-signaling in cancer. Biochim Biophys Acta 2003, 1653:1-24.
10. Weinstein M, Monga SP, Liu Y, et al. Smad proteins and hepatocyte growth factor control parallel regulatory pathways that converge on beta1-integrin to promote normal liver development. Mol Cell Biol 2001, 21:5122-5131.
11. Clotman F, Jacquemin P, Plumb-Rudewiez N, et al. Control of liver cell fate decision by a gradient of TGF beta signaling modulated by Onecut transcription factors. Genes Dev 2005, 19:1849-1854.
12. Dooley S, Weng H, Mertens PR. Hypotheses on the role of transforming growth factor-beta in the onset and progression of hepatocellular carcinoma. Diq Dis 2009, 27:93-101.
13. Calmont A, Wandzioch E, Tremblay KD, et al. An FGF response pathway that mediates hepatic gene induction in embryonic endoderm cells. Dev Cell 2006, 11:339-348.
14. Matsuda Y, Ichida T. Impact of hepatitis B virus X protein on the DNA damage response during hepatocarcinogenesis. Med Mol Morphol 2009, 42:138-142.
15. Ito Y, Matsui T, Kamiya A, et al. Retroviral gene transfer of signaling molecules into murine fetal hepatocytes defines distinct roles for the STAT3 and ras pathways during hepatic development. Hepatology 2000, 32:1370-1376.
16. Wurmbach E, Chen YB, Khitrov G, Zhang W, Roayaie S, Schwartz M, Fiel I, Thung S, Mazzaferro Y, Bruix J, Bottinger E, Friedman S, Waxman S, Llovet JM. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 2007, 45:938-9347.
17. Lemaigre FP. Notch Signaling in Bile Duct Development: New Insights Raise New Questions. Hepatology 2008, 48:358-360.
18. Wang M, Xue L, Cao Q, Lin Y, Ding Y, Yang P, Che L. Expression of Notch1, Jagged1 and β-catenin and their clilicopathological significance in hepatocellular carcinoma. Neoplasma 2009, 56:533-541.
19. Hirose Y, Itoh T, Miyajima A. Hedgehog signal activation coordinates proliferation and differentiation of fetal liver progenitor cells. Exp Cell Res 2009, 315:2648-2657.
20. Cheng WT, Xu K, Tian DY, Zhang ZG, Liu LJ, Chen Y. Role of Hedgehog signaling pathway in proliferation and invasiveness of hepatocellular carcinoma cells. Int J Oncol 2009, 34:829-836.
21. Li T, Huang J, Jiang Y, Zeng Y, He F, Zhang MQ. Multi-stage analysis of gene expression and transcription regulation in C57/B6 mouse liver development. Genomics 2009, 93:235-242.
22. Li T, Wan B, Huang J, Zhang X. Comparison of gene expression in hepatocellular carcinoma, liver development, and liver regeneration. Mol Genet Genomics 2010, 283(5):485-492.
23. Xu H, He JH, Xiao ZD, Zhang QQ, Chen YQ, Zhou H, Qu LH. Liver-enriched transcription factors regulate microRNA-122 that targets CUTL1 during liver development. Hepatology 2010, 52(4):1431-1442.
24. Yamashita T, Ji J, Budhu A, Forgues M, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009, 136:1012-1024.
25. Dan YY, Yeoh GC. Liver stem cells: a scientific and clinical perspective. J Gastroenterol Hepatol 2008, 23:687-698.
26. Chiba T, Miyagi S, Saraya A, Aoki R, Seki A, Morita Y, Yonemitsu Y, Yokosuka O, Taniguchi H, Nakauchi H, Iwama A. The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma. Cancer Res 2008, 68:7742-7749.
27. Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T, Durnez A, Demetris AJ, Thorgeirsson SS. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004, 40:667-676.
28. Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, Jia H, Budhu A, Zanetti KA, Chen Y, Qin LX, Tang ZY, Wang WX. EpCAM and A-Fetoprotein Expression Defines Novel Prognostic Subtypes of Hepatocellular Carcinoma. Cancer Res 2008, 68:1451-1461.
29. Kanehisa M. A database for post-genome analysis. Trends Genet 1997, 13:375-376.
30. Kanehisa M, Goto S. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res 2000, 28:27-30.
31. Teufel A, Weinmann A, Krupp M, Budinger M, Galle PR. Genome-wide analysis of factors regulating gene expression in liver. Gene 2007, 389:114-121.
32. Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF, Mikaelyan A, Roberts LR, Demetris AJ, Sun Z, Nevens F, Roskams T, Thorgeirsson SS. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006, 12:410-416.
33. Ivanovska I, Zhang C, Liu AM, et al. Gene signatures derived from a c-MET-driven liver cancer mouse model predict survival of patients with hepatocellular carcinoma. PLoS One 2011, 6(9):e24582.
34. McShane LM, Radmacher MD, Freidlin B, Yu R, Li MC, Simon R. Methods for assessing reproducibility of clustering patterns observed in analyses of microarray data. Bioinformatics 2002, 18(11):1462-1469.
35. Lemaigre FP. Mechanisms of Liver Development: Concepts for Understanding Liver Disorders and Design of Novel Therapies. Gastroenterology 2009, 137:62-79.
36. Larsen M, Artym VV, Green JA, Yamada KM. The matrix reorganized: extracellular matrix remodeling and integrin signaling. Curr Opin Cell Biol 2006, 18:463-471.
37. Meighan CM, Schwarzbauer JE. Temporal and spatial regulation of integrins during development. Curr Opin Cell Biol 2008, 20:520-524.
38. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004, 126:460-468.
39. Ikeda Y, Shimada M, Hasegawa H, Gion T, Kajiyama K, Shirabe K, et al. Prognosis of hepatocellular carcinoma with diabetes mellitus after hepatic resection. Hepatology 1998, 27:1567-1571.
40. Ohki T, Tateishi R, Sato T, Masuzaki R, Imamura J, Goto T, Yamashiki N, Yoshida H, Kanai F, Kato N, Shiina S, Yoshida H, Kawabe T, Omata M. Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients. Clin Gastroenterol Hepatol 2008, 6:459-464.
41. Teufel A, Galle PR. Collecting evidence for a stem cell hypothesis in HCC. Gut 2010, 59(7):953-962.
42. Khetchoumian K, Teletin M, Tisserand J, Mark M, et al. Loss of Trim24 (Tif1alpha) gene function confers oncogenic activity to retinoic acid receptor alpha. Nat Genet 2007, 39(12):1500-1506.
43. Irizarry RA. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4:249-264.